Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech
Mandate

Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

October 29, 2018 Capital Markets and Public M&A

Galecto Biotech AB, the developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, has closed a €79 million financing co-led by Ysios Capital and OrbiMed.

New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round.
 
Vinge advised the new investors. The Vinge team included Jesper Ottergren, Erik Sjöman and Charlotte Akej.
 

Related

Vinge advises Karl Hedin and the minority owners in connection with the sale of AS Toftan to Combiwood

 Vinge has advised Karl Hedin and the minority owners in connection with the sale of AS Toftan to Combiwood Grupp OÜ (“Combiwood”).
May 22, 2025

Vinge has advised the FEA Group, which includes Freys Hyrverk and Stockholm Limousine Service, in connection with its merger with Inclusion Services International

 The merger strengthens the new FEA Group’s capacity and service offering, which includes everything from comprehensive travel planning and hotel bookings to security-classified passenger transport and risk assessments. According to management, the newly formed group will have a unique position in the Swedish market with the opportunity to introduce new transport and security solutions that are currently unmatched in the country.
May 21, 2025

Vinge advises EHF Invest on its public offer for Real Fastigheter

 EHF Invest AB has made a public offer for all shares in Real Fastigheter AB (publ).
May 21, 2025